Afatinib and Necitumumab in <i>EGFR</i>-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.

ABSTRACT:

Introduction

Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing EGFR gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in EGFR-mutated NSCLC that has progressed on TKI therapy alone. Therefore, we prospectively evaluated afatinib plus necitumumab in patients with EGFR-mutated NSCLC.

Methods

This was a phase 1, dose-escalation, dose-expansion trial assessing the safety and efficacy of afatinib plus necitumumab. Patients had advanced or metastatic EGFR-mutated NSCLC with progression after (1) first-generation TKI if T790M negative, (2) subsequent line third-generation TKI if T790M positive, or (3) third-g

SUBMITTER: Myall NJ 

PROVIDER: S-EPMC11759541 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature